Alumni Ventures’ Track Record of Investing in Foundational Tech

Learn about some of our exciting portfolio companies developing innovative solutions for tech infrastructure

Published on

Read

5 min

AV has invested in more than 1,200 startups developing both foundational and disruptive tech. Learn about some of our exciting portfolio companies developing innovative solutions in artificial intelligence, biotech, and quantum computing


Meet Our Foundational Tech Investments

Our investing teams discuss and interview some of our most innovative portfolio companies

Interested in Investing in Startups Like This?

Reserve Your Spot in Deep Tech Fund 4

We are seeing strong interest in our Deep Tech Fund. If interested, we recommend securing a spot promptly.

Investors in the fund will own a portfolio of high-tech game-changers and disruptive business models using advanced science and engineering to tackle the toughest and potentially most lucrative tech challenges.

Max Accredited Investor Limit: 249
Deadline to Join: December 31, 2023

Venture capital allows accredited investors to back innovative startups disrupting a variety of industries. The work of these companies is powered by foundational technologies — groundbreaking inventions that enable significant societal improvement. For example, foundational tech like artificial intelligence allows for the creation of disruptive AI-powered solutions like consumer chatbots, generative art, and drug discovery.

Alumni Ventures has invested in more than 1,200 venture-backed startups developing both foundational and disruptive tech. Below, we focus on just three sectors — AI, biotech, and quantum computing — where we believe our portfolio companies are developing particularly impactful tech solutions.

Artificial Intelligence

The rapid adoption of AI has left few parts of the economy untouched. The potential of AI, machine learning, and big data technology promises to reshape and disrupt the creation of art and media, medicine, law, and other age-old disciplines. PwC found that AI could contribute up to $15.7 trillion to the global economy by 2030 — “more than the current output of China and India combined.” According to McKinsey, the economic value of generative AI alone could be as much as $4.4 trillion.

Sample AV Artificial Intelligence Investments

Bionic Health is developing a consumer health platform powered by GPT-4. With the help of Microsoft, Bionic plans to scale its services by augmenting doctors with AI to deliver optimal health guidance. Read More »

How We’re Involved

  • $3 million seed round in 2023, with participation from IDEA Fund Partners, Studio VC, Tweener Fund, AI Operator’s Fund, and Operator.VC

AV Funds Invested in Bionic Health

Managing Partner Greg Baker on Bionic Health

See video policy below.

Venture Deep Dives: AI in Healthcare

Our “Deep Dives” series explores vital aspects of the burgeoning VC sector with one of AV’s ~50 investing experts. In this episode, Senior Principal Emeritus Isaac Schlecht discusses the impact of AI on the healthcare industry.

See video policy below.

Cohere has developed an adaptable API that empowers companies of all sizes to enhance their workflows with NLP. The company was founded by leading AI researchers from Google and has attracted support from several established VCs and enterprise partners in the AI space. Read More »

How We’re Involved

  • $270 million Series C in 2023 led by Inovia Capital, with participation from Nvidia, Oracle, Salesforce Ventures, Index Ventures, and others

AV Funds Invested in Cohere

Managing Partner Todd McIntyre on Cohere

See video policy below.

Biotech

Advancements in biotech, healthtech, and life sciences have vastly improved our quality of life, longevity, and how we treat and cure significant diseases. These innovative solutions are projected to drive the biotech market to nearly $4 trillion by 2030. Gene therapy is an exciting advancement in biotech, where direct cellular therapies help treat or cure patients with inherited or acquired genetic diseases like hemophilia or leukemia. Medical isotopes are another promising focus of biotech research, with the potential to treat diseases like cancer while producing fusion energy.

Sample AV Biotech Investments

American Gene Technologies is developing gene and cell therapy drugs that treat infectious diseases, monogenic disorders, and cancers. The drugs use a proprietary gene-delivery platform to develop patented gene and cell therapies that cure these diseases. Read More »

How We’re Involved

AV Funds Invested in American Gene Technologies

A Conversation with Founder and CEO Jeff Galvin

See video policy below.

Excision Bio is focused on developing advanced gene-editing therapeutics to treat life-threatening viral infections. The company’s CRISPR-based therapies eliminate viral genomes from infected individuals. Read More »

How We’re Involved

  • $10 million seed round in 2017 led by ARTIS Ventures, with participation from Bioverge Ventures, Gaingels, and others
  • $60 million Series A in 2021 led by GreatPoint Ventures, with participation from Norwest Venture Partners and others

AV Funds Invested in Excision Bio

SHINE Technologies deploys its safe, cost-effective, and environmentally friendly fusion technology to develop medical isotopes for heart disease and cancer treatment. In the future, SHINE will apply its technology to recycle nuclear waste to achieve its ultimate goal: producing fusion energy. Read More »

How We’re Involved

AV Funds Invested in SHINE Medical

Webinar
Harnessing Nuclear Fusion to Produce Critical Medicine: A Conversation with Greg Piefer CEO of Shine Technologies

Presenters
Greg Baker
Greg Baker

Managing Partner, Bascom Ventures & Towerview Ventures

Greg Piefer
Greg Piefer

Founder & CEO, SHINE Technologies

Quantum Computing

Unlike traditional computing solutions, quantum computers can process far more data through the use of superposition (the ability of a system to be in multiple states at the same time) and entanglement (when a particle correlates with the characteristics of the others). This opens up significant improvements in how enterprises develop solutions for cybersecurity, financial modeling infrastructure optimization, and more — with the potential to become a $700 billion market by 2035.

Sample AV Quantum Computing Investments

Xanadu is a leading quantum computing hardware and software developer, offering a cloud-accessible, state-of-the-art computing platform. Taking a full-stack approach, the company builds photonics-based quantum computer hardware and its own multi-platform software that can be easily scaled for large and complex scientific and industrial computing applications. Learn More »

How We’re Involved

  • $100 million Series C in 2022 led by Georgian, with participation from Porsche Automobil Holding SE, Bessemer Venture Partners, and others

AV Funds Invested in Xanadu

Roundtable with AV Quantum Computing Portfolio Companies

See video policy below.

Zapata AI has developed a hardware and software stack that lets corporations use AI and quantum computing to address their hardest problems. The company tailors solutions to enterprises’ domain-specific, industrial-scale business problems to drive growth, savings, and unprecedented insight. Read More »

How We’re Involved

  • $38 million Series B in 2020 led by Comcast Ventures, Pitango, and Prelude Ventures, with participation from The Engine Accelerator Fund, Merck Global Health Innovation Fund, and others

AV Funds Invested in Zapata

Interested in Investing in Startups Like This?

Reserve Your Spot in Deep Tech Fund 4

We are seeing strong interest in our Deep Tech Fund. If interested, we recommend securing a spot promptly.

Investors in the fund will own a portfolio of high-tech game-changers and disruptive business models using advanced science and engineering to tackle the toughest and potentially most lucrative tech challenges.

Max Accredited Investor Limit: 249
Deadline to Join: December 31, 2023

Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit av-funds.com/disclosures.